STOCK TITAN

MariMed (MRMD) director awarded 192,308 RSUs converting to shares

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

MARIMED INC. director Allen David R received 192,308 Restricted Stock Units on July 15, 2026 in lieu of a portion of his board fees. The RSUs vested upon grant and converted one-for-one into 192,308 shares of common stock at no cash exercise price, increasing his direct holdings to 743,452 shares. No RSUs from this award remain outstanding.

Positive

  • None.

Negative

  • None.
Insider Allen David R
Role Director
Type Security Shares Price Value
Grant/Award Restricted Stock Units (RSU) 192,308 $0.00 --
Exercise Restricted Stock Units (RSU) 192,308 $0.00 --
Exercise Common stock 192,308 $0.00 --
Holdings After Transaction: Restricted Stock Units (RSU) — 192,308 shares (Direct); Common stock — 743,452 shares (Direct)
Footnotes (1)
  1. RSUs convert to shares of common stock on a one-for-one basis. The RSUs were granted on July 15, 2026 and vested upon grant in accordance with the terms of the award agreement between the Issuer and the Reporting Person. Accordingly, no RSUs remain outstanding under this award.
RSUs granted 192,308 units Restricted Stock Units granted on July 15, 2026 in lieu of board fees
Common shares acquired 192,308 shares Shares of common stock received upon RSU vesting and conversion on July 15, 2026
Total shares held after transaction 743,452 shares Direct holdings of MariMed common stock by Allen David R following the RSU conversion
Exercise price per share $0.00 per share Cash exercise price for conversion of RSUs into common stock
Underlying common shares per RSU 1 share per RSU RSUs convert to shares of common stock on a one-for-one basis
Restricted Stock Units (RSU) financial
"The RSUs were granted in lieu of cash as payment for a portion"
derivative security financial
"transaction_action": "derivative exercise/conversion""
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
in lieu of cash financial
"RSUs were granted in lieu of cash as payment for a portion"
Rule 10b5-1 financial
"aff_10b5_one is the filing's document-level Rule 10b5-1 checkbox"
Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What insider equity compensation did MariMed (MRMD) director Allen David R receive?

Allen David R received 192,308 Restricted Stock Units on July 15, 2026 as compensation for a portion of his MariMed board fees. These RSUs vested immediately and converted one-for-one into 192,308 shares of common stock at no cash exercise price.

How many MariMed (MRMD) shares does Allen David R hold after these transactions?

Following the RSU grant and conversion, Allen David R directly holds 743,452 shares of MariMed common stock. This total reflects the addition of 192,308 shares received upon the vesting and conversion of his Restricted Stock Units granted as director compensation.

How did the 192,308 RSUs for MariMed (MRMD) convert into common shares?

The 192,308 RSUs convert into MariMed common stock on a one-for-one basis, as disclosed. Upon grant on July 15, 2026, the RSUs vested immediately and were exercised or converted into 192,308 shares of common stock with no cash exercise price.

Do any RSUs from this MariMed (MRMD) award remain outstanding for Allen David R?

No RSUs from this award remain outstanding. The footnotes state that the 192,308 RSUs granted on July 15, 2026 vested upon grant and, accordingly, no RSUs remain outstanding under this award after their conversion into common shares.

Why were RSUs used instead of cash to compensate the MariMed (MRMD) director?

The company states the RSUs were granted in lieu of cash as payment for a portion of Allen David R’s fees for serving on MariMed’s Board of Directors, effectively delivering board compensation in equity rather than in cash.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Allen David R

(Last)(First)(Middle)
C/O MARIMED INC.
10 OCEANA WAY

(Street)
NORWOOD MASSACHUSETTS 02062

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
MARIMED INC. [ MRMD ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/15/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common stock07/15/2026M192,308A$0(1)743,452D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Units (RSU)(1)07/15/2026A192,308 (2) (2)Common Stock, par value $.001 per share192,308$0192,308D
Restricted Stock Units (RSU)(1)07/15/2026M192,308 (2) (2)Common Stock, par value $.001 per share192,308$00D
Explanation of Responses:
1. RSUs convert to shares of common stock on a one-for-one basis.
2. The RSUs were granted on July 15, 2026 and vested upon grant in accordance with the terms of the award agreement between the Issuer and the Reporting Person. Accordingly, no RSUs remain outstanding under this award.
Remarks:
The RSUs were granted in lieu of cash as payment for a portion of the Reporting Person's fees for serving on the Issuer's Board of Directors.
/s/ David R. Allen07/16/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)